In this article, we will list the 5 Most Volatile Penny Stocks to Buy Now. Please visit 10 Most Volatile Penny Stocks to Buy Now if you would like to see the extended list and the methodology behind it.
5. Virgin Galactic Holdings, Inc. (NYSE:SPCE)
On May 27, 2026, Virgin Galactic Holdings, Inc. (NYSE:SPCE) said VSS Unity, its prototype Spaceship, returned to the skies above Spaceport America in New Mexico for the first of several expected glide flights. The company said the flights are intended to prepare pilots and operations teams ahead of new Spaceship operations and the first flight test of its next-generation Spaceship.
On May 17, 2026, Jefferies said Virgin Galactic Holdings, Inc. (NYSE:SPCE) showed progress in Q1 as its first Delta spaceship moves toward commercial service in Q4, with ground testing scheduled for Q2 and flight tests beginning in Q3. Jefferies also noted that Virgin reopened ticket sales for a limited number of spaceflight expeditions priced at $750,000 per ticket, with an expected Q3 close. The firm said the company’s cash position “provides a window of safety” and maintained a Buy rating with a $5 price target.
On May 14, 2026, Virgin Galactic Holdings, Inc. (NYSE:SPCE) reported Q1 EPS of (81c), compared to estimates of (94c). Revenue totaled $227K, below the consensus estimate of $240K. CEO Michael Colglazier said the company delivered the first of its new SpaceShips from its Assembly hangar to its Test-and-Launch hangar, with ground testing underway. Colglazier added that Virgin Galactic remains on track to begin flight testing in Q3 and spaceflight in Q4.
Virgin Galactic Holdings, Inc. (NYSE:SPCE) focuses on the development, manufacture, and operation of spaceships and related technologies.
4. Enhanced Group Inc. (NYSE:ENHA)
On May 18, 2026, Enhanced Group Inc. (NYSE:ENHA) announced a strategic partnership with Rezolve AI to build out Live Enhanced, its direct-to-consumer digital telehealth platform. The collaboration covers AI technologies, digital consumer engagement, and event sponsorship. Enhanced said it is building the platform with AI-enabled infrastructure from the start, including AI medical concierge capabilities and AI-driven insights. Rezolve will also build the Enhanced Games mobile-first website.
On May 11, 2026, Lucid Capital analyst Alex Fuhrman initiated coverage of Enhanced Group Inc. (NYSE:ENHA) with a Buy rating and a $15 price target on the shares. Fuhrman said demand for longevity treatments has been rising and that Enhanced has a plan to bring “exclusive concierge-level care into the mainstream.” Lucid Capital said the company is well-positioned to benefit from longevity demand through its scalable direct-to-consumer platform.
Enhanced Group Inc. (NYSE:ENHA) designs and produces multisport live events under the Enhanced Games brand in the United States.
3. Prelude Therapeutics Incorporated (NASDAQ:PRLD)
On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with an Early-Stage Biotech rating. Johnson said the company’s “differentiated approach” in metastatic breast cancer could unlock a $10B opportunity.
On May 12, 2026, Prelude Therapeutics Incorporated (NASDAQ:PRLD) reported Q1 EPS of (13c), compared to the consensus estimate of (27c). CEO Kris Vaddi said the company continued to show “focused execution” against the strategic priorities it set late last year. Vaddi cited the advancement of PRT12396 into first-in-human studies, preclinical data from its KAT6A degrader development candidate, progress toward a development candidate from its mCALR program, and a cash runway extended into the second quarter of 2028.
On May 4, 2026, D. Boral Capital initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with a Buy rating and a $9 price target. D. Boral described Prelude as a clinical-stage oncology company advancing a precision medicine approach through a pipeline targeting epigenetic and DNA damage response pathways. The firm cited the company’s “deep pipeline,” emerging clinical validation, and multiple near-term catalysts, while also saying Prelude has validated its JAK2 franchise through a program-specific agreement with Incyte.
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is a clinical-stage precision oncology company focused on developing novel precision cancer medicines for underserved patients.
2. LiveWire Group, Inc. (NYSE:LVWR)
On May 19, 2026, LiveWire Group, Inc. (NYSE:LVWR) announced that it acquired the assets of Dust Moto. LiveWire Group, Inc. (NYSE:LVWR) said that the acquisition supports its strategy to expand beyond on-road electric motorcycles and enter the electric off-road market. The company also said it is advancing Dust’s electric dirt bike platform toward production, using LiveWire’s engineering capabilities, manufacturing scale, and global marketing, sales, and service network.
On May 5, 2026, LiveWire Group, Inc. (NYSE:LVWR) reported Q1 EPS of (9c), compared to (9c) last year. Revenue totaled $5.115M, up from $2.743M last year. Chief Executive Officer Karim Donnez said revenue increased 86% year-over-year, helping improve gross profit, operating loss, and free cash flow. Donnez also said LiveWire Group, Inc. (NYSE:LVWR) maintained its position as the number one retailer of U.S. electric on-road motorcycles and pointed to the upcoming launch of the S4 Honcho.
LiveWire Group, Inc. (NYSE:LVWR) manufactures and sells electric motorcycles in the United States, Austria, and internationally.
1. InflaRx N.V. (NASDAQ:IFRX)
On May 13, 2026, Raymond James upgraded InflaRx N.V. (NASDAQ:IFRX) to Strong Buy from Outperform with a price target of $9, up from $7. Raymond James said sentiment is increasingly supported by a constructive view of InflaRx’s izicopan program in AAV, backed by a recent $150M financing that extends runway into proof-of-concept development. The firm also cited preclinical and early clinical signals suggesting potentially improved potency, reduced hepatotoxicity risk, and simpler dosing versus avacopan.
On May 11, 2026, H.C. Wainwright analyst Matthew Keller raised the firm’s price target on InflaRx N.V. (NASDAQ:IFRX) to $8 from $6 and maintained a Buy rating on the shares. Keller cited the company’s adjusted clinical focus on ANCA-associated vasculitis, inflammatory renal diseases, and potential partnering of the hidradenitis suppurativa program following the recent corporate update.
On May 6, 2026, InflaRx N.V. (NASDAQ:IFRX) announced plans to develop izicopan, an oral C5a receptor inhibitor, in AAV, a life-threatening kidney disorder. The company is conducting Phase 2 planning for izicopan in AAV and evaluating multiple development approaches, including a potential expedited path to the commercial market. InflaRx also aims to establish rapid proof of concept for izicopan across a broader range of complement-mediated life-threatening kidney diseases through open-label studies expected to begin generating clinical data next year in certain indications.
InflaRx N.V. (NASDAQ:IFRX) discovers and develops inhibitors using C5a technology in Germany and the United States.
While we acknowledge the potential of IFRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IFRX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 High Growth Stocks to Buy and Hold for the Next Decade and 12 Strong Buy Stocks to Buy and Hold for the Next 5 Years
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
